Blood-brain barrier penetration of zolmitriptan - Modelling of positron emission tomography data

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 1, 2006, Pages 75-91

  Bergström, Mats ^a,b,c   Yates, Roger ^d,e   Wall, Anders ^a   Kågedal, Matts ^d   Syvänen, Stina ^a,b   Långström, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NOVARTIS PHARMA AG   (Switzerland)

^d ASTRAZENECA   (United Kingdom)

^e RayCandoc Ltd   (United Kingdom)

Author keywords

Brain; Convolution; Modelling; Pharmacokinetics; Positron emission tomography; Zolmitriptan

Indexed keywords

CARBON 11; ZOLMITRIPTAN;

ARTERIAL BLOOD; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG PENETRATION; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; VENOUS BLOOD;

BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; OXAZOLIDINONES; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN AGONISTS; TISSUE DISTRIBUTION; TRYPTAMINES;

EID: 33645890579     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-9001-1     Document Type: Article

References (33)

1. 11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomograph. Clin. Pharmacokinet. 36:33-39 (1999).
2. O. Gefvert, M. Bergstrom, B. Langstrom, T. Lundberg, L. Lindstrom, and R. Yates. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135:119-126 (1998).
3. O. Gefvert, T. Lundberg, I. M. Wieselgren, M. Bergstrom, B. Langstrom, F. Wiesel, and L. Lindstrom. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharm. 11:105-110 (2001).
4. P. Hartvig, M. Bergstrom, G. Antoni, and B. Langstrom. Positron emission tomography and brain monoamine neurotransmission-entries for study of drug interactions. Curr. Pharm. Des. 8:1417-1434 (2002).
5. (11)C-carbamoyl compounds. J. Org. Chem. 67:3687-3692 (2002).
6. S. M. Learned-Coughlin, M. Bergstrom, I. Savitcheva, J. Ascher, V. D. Schmith, and B. Langstrom. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry. 54:800-805 (2003).
7. L. J. Lesko, M. Rowland, C. C. Peck, and T. F. Blaschke. Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. Pharm. Res. 17:1335-1344 (2000).
8. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, J. H. Rodman et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Pharm. Sci. 81:605-610 (1992).
9. A. A. Lammertsma. Radioligand studies: Imaging and quantitative analysis. Eur. Neuropsychopharm. 12:513-516 (2002).
10. 11C]zofenoprilat. Bioorg. Med. Chem. 12:603-611 (2004).
11. O. C. Hutchinson, D. R. Collingridge, H. Barthel, P. M. Price, and E. O. Aboagye. Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. Curr. Pharm. Des. 9:931-944 (2003).
12. D. J. Propper, J. de Bono, A. Saleem, S. Ellard, E. Flanagan, J. Paul, T. S. Ganesan, D. C. Talbot, E. O. Aboagye, P. Price, A. L. Harris, and C. Twelves. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J. Clin. Oncol. 21:203-210 (2003).
13. 11C] vinpocetine in human subjects. Acta. Neurol. Scand. 106:325-332 (2002).
14. M. Bergstrom, A. Grahnen, and B. Langstrom. Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug developmet. Eur. J. Clin. Pharmacol. 59:357-366 (2003).
15. 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin. Pharmacol. Ther. 57:309-317 (1995).
16. N. Uemura, B. R. Charlesworth, T. Onishi, A. Mitaniyama, T. Kaneko, K. Ninomiya, K. Nakamura, and M. Tateno. Zomitriptan is detectable in plasma as early as 2 to 5 minutes after administration by nasal spray. Ann. Meeting Prog. Abstr. Headache: J. Head Face Pain 43:509-592, S159 (2003).
17. M. Kågedahl, T. Duvauchelle, L. Hovesepian, B. R. Charlesworth, H.-L. Su, and R. A. Yates. Zolmitriptan demonstrates good pharmacokinetic consistency between and within individuals following intranasal administration. pA2 [serial online] 1: abstract 211P. Available from http://www.pa2online.org/ (2003).
18. M. Gawel, J. Aschoff, A. May, and B. R. Charlesworth. Zolmitriptan Nasal Spray: Efficacy, Onset of Action and Patient Satisfaction in Phases I and II of the REALIZE Study. Ann. Meeting Prog. Abstr. Headache: J. Head Face Pain 44:457-536, F23 (2004).
19. A. Wall, M. Kagedal, M. Bergstrom, E. Jacobsson, D. Nilsson, G. Antoni, P. Frandberg, S-A. Gustavsson, B. Langstrom, and R. Yates. Distribution of Zolmitriptan into the CNS in healthy volunteers. A positron emission tomography study. Drugs R D 6:139-147, (2005).
20. W. F. Ebling, D. R. Wada, and D. R. Stanski. From piecewise to full physiologic pharmacokinetic modeling: Applied to thiopental disposition in the rat. J. Pharmacokinet. Biopharm. 22:259-292 (1994).
21. D. Verotta. An inequality-constrained least-squares deconvolution method. J. Pharmacokinet. Biopharm. 17:269-289 (1989).
22. M. Pitsiu, J. M. Gries, N. Benowitz, S. G. Gourlay, and D. Verotta. Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: Application to smokeless tobacco and nicotine gum. J. Pharmacokinet. Pharmacodyn. 29:383-402 (2002).
23. R. N. Gunn, S. R. Gunn, and V. J. Cunningham. Positron emission tomography compartmental models. J. Cereb. Blood Flow Metab. 21:635-652 (2001).
24. R. N. Gunn, S. R. Gunn, F. E. Turkheimer, J. A. Aston, and V. J. Cunningham. Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J. Cereb. Blood Flow Metab. 22:1425-1439 (2002).
25. V. J. Cunningham, and T. Jones. Spectral analysis of dynamic PET studies. J. Cereb. Blood Flow Metab. 13:15-23 (1993).
26. T. O'Hara, S. Hayes, J. Davis, J. Devane, T. Smart, and A. Dunne. In vivo-in vitro correlation (IVIVC) modeling incorporating a convolution step. J. Pharmacokinet. Pharmacodyn. 28:277-298 (2001).
27. R. Gomeni, C. Dangeli, and A. Bye. In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation. Pharm. Res. 19:99-103 (2002).
28. W. L. Chiou, G. Lam, M. L. Chen, and M. G. Lee. Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. Res. Commun. Chem. Pathol. Pharmacol. 32:27-39 (1981).
29. H. C. Porchet, N. L. Benowitz, L. B. Sheiner, and J. R. Copeland. Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. J. Clin. Invest. 80:1466-1471 (1987).
30. B. Tuk, V. M. Herben, J. W. Mandema, and M. Danhof. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. J. Pharmacol. Exp. Ther. 284:202-207 (1998).
31. 11C[SCH23390]: A test-retest analysis. J. Cereb. Blood Flow Metab. 21:1133-1145 (2001).
32. 11C]FLB 457-A test-retest analysis. Eur. J. Nucl. Med. 27:1666-1673 (2000).
33. 11C]-raclopride in vivo: A test-retest analysis. J. Cereb. Blood Flow Metab. 19:210-217 (1999).